John Welborn , Jr. is appointed Chair of the Board, succeedingGreg Gubitz , who is retiringJohn Hanna is appointed to the HLS Board as an independent director
"On behalf of the Board and HLS employees, I want to thank Greg for his service and many contributions to HLS as a co-founder, former CEO, and most recently as Chair over the past year. Under his recent leadership as Chair, the Board hired a new CEO and reshaped and streamlined the Board of Directors, adding both more shareholder representation and industry expertise," said John Welborn, Chair of the Board at HLS.
"We also welcome
"Mental health and cardiovascular disease are significant issues for many Canadians, and HLS is committed to serving our patients with life-improving and life-saving therapies. As a Board, we are excited for our new CEO, Craig Millian, to optimize our product portfolio and lead HLS. The Board is committed to ensuring profitable growth and improving shareholder value," said
The HLS Board now has eight members:
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases, the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to the composition of HLS's board of directors. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated
SOURCE
© Canada Newswire, source